

Substitute for Form 1449 A &amp; B/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/519,102
Confirmation Number	NOT YET ASSIGNED
Filing Date	December 27, 2004
First Named Inventor	MIKOSHIBA, Imao
Art Unit	NOT YET ASSIGNED
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	Q85257

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
/M.F./		US 2003/0040490	A1	02-27-2003	SUGIYAMA ET AL
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
/M.F./		EP	1 179 342	A1	02-13-2002	Kissei Pharmaceutical Co., Ltd	English
/M.F./		JP	2000-26292		01-25-2000	Kissei Pharmaceutical Co., Ltd.	Abstract

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Japanese Journal of Clinical Medicine, 1997, Special extra issue, Vol. 55, pp. 171-179	No
/M.F./		Drugs of the Future, 2000, Vol. 20, No. 10, pp. 1034-1042	English

Examiner Signature	/Meghan Finn/	Date Considered	05/21/2007
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

<b>Notice of References Cited</b>	Application/Control No. 10/519,102		Applicant(s)/Patent Under Reexamination MIKOSHIBA ET AL.	
	Examiner Meghan Finn		Art Unit 1609	Page 1 of 1

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,133,454	10-2000	Lecouve et al.	548/515
*	B	US-2003/0073729	04-2003	Kitahara et al.	514/369
*	C	US-2004/0002544	01-2004	Makino et al.	514/563
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 03/061650 A1 ✓	07-2003	FRANCE	Wuthrich et al.	-----
	O	EP 1179342 A1 ✓	02-2002	European Patent	OUCHI' et al.	-----
	P	WO 00/71117 ✓	11-2000	WIPO	Ouchi et al.	-----
	Q					
	R					
	S					
	T					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ohnota et al., Novel Rapid- and Short-Acting Hypoglycemic Agent, a Calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylicarbonyl)Propionate(KAD-1229) That Acts on the Sulfonylurea Receptor: Comparison of Effects Between KAD-1229 and Gliclazide; 1994, The Journal of Pharmacology and Experimental Therapeutics, 269 (2), p 489-495. ✓
	V	Landgraf et al., A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. 1999, European Journal of Clinical Pharmacology, 55, p 165-171. ✓
	W	Evans et al., Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus, 1999, Drugs in R&D, 2(2), p. 75-91. ✓
	X	Yamaguchi et al., Preparation of Optically Active Succinic Acid Derivatives. 1. Optical resolution of 2-Benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)-propionic acid, 1997, Chemical and Pharmaceutical Bulletin, 45(9), p. 1518-1520. ✓

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.